<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409080</url>
  </required_header>
  <id_info>
    <org_study_id>R7257-RAA-1947</org_study_id>
    <secondary_id>2020-002031-29</secondary_id>
    <nct_id>NCT04409080</nct_id>
  </id_info>
  <brief_title>REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy</brief_title>
  <official_title>A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of REGN7257 in&#xD;
      patients with severe aplastic anemia (SAA) that is refractory to or has relapsed while on&#xD;
      standard of care immunosuppressive therapy (IST). An additional primary objective (for Part B&#xD;
      only) is to evaluate the clinical efficacy of REGN7257 in IST-refractory/relapsed patients.&#xD;
&#xD;
      The secondary objectives of this study are to assess the following for REGN7257:&#xD;
&#xD;
        -  Clinical response over time&#xD;
&#xD;
        -  Maintenance of response&#xD;
&#xD;
        -  Impact on transfusion requirements&#xD;
&#xD;
        -  Effect on blood counts and cell populations&#xD;
&#xD;
        -  Pharmacokinetics (PK)&#xD;
&#xD;
        -  Immunogenicity&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">August 8, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>12 months post-treatment, approximately 52 weeks</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>12 months post-treatment, approximately 52 weeks</time_frame>
    <description>Parts A and B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) up</measure>
    <time_frame>12 months post-treatment, approximately 52 weeks</time_frame>
    <description>Parts A and B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>6 months post-treatment, approximately 26 weeks</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months post-treatment, approximately 12 weeks</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>3 months post-treatment, approximately 12 weeks</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response (PR)</measure>
    <time_frame>3 months post-treatment, approximately 12 weeks</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to best response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who maintain any clinical response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet transfusions per month over time</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell transfusions per month over time</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte cell counts</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in neutrophil cell counts</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hemoglobin cell counts</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in reticulocyte cell counts</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in platelet cell counts</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the whole blood immune cell subsets (T cells)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the whole blood immune cell subsets (B cells)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the whole blood immune cell subsets (NK cells)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentrations in serum over time</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-drug antibody (ADA) over time</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Parts A and B</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Severe Aplastic Anemia (SAA)</condition>
  <arm_group>
    <arm_group_label>Part A and Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Single ascending dose Part B: Preferred dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN7257</intervention_name>
    <description>Single dose will be administered by intravenous IV infusion</description>
    <arm_group_label>Part A and Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  SAA that is refractory to or has relapsed while on standard of care IST, as defined in&#xD;
             the protocol&#xD;
&#xD;
          -  Hematopoietic stem cell transplantation (HSCT) is not available or suitable as a&#xD;
             treatment option or has been refused by the patient&#xD;
&#xD;
          -  Adequate hepatic and renal function as defined in the protocol&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Fanconi anemia as defined in the protocol&#xD;
&#xD;
          -  Evidence of myelodysplastic syndrome as defined in the protocol&#xD;
&#xD;
          -  Paroxysmal nocturnal hemoglobinuria (PNH) with evidence of clinically significant&#xD;
             hemolysis (eg, treatment indicated) or history of PNH-associated thrombosis&#xD;
&#xD;
          -  Treatment with a T cell-depleting agent (eg, ATG or alemtuzumab) within 6 months prior&#xD;
             to dosing&#xD;
&#xD;
          -  Treatment with a calcineurin inhibitor (eg, cyclosporine) within 4 weeks prior to&#xD;
             dosing&#xD;
&#xD;
          -  Treatment with eltrombopag or investigational thrombopoietin receptor agonist,&#xD;
             Granulocyte Colony-Stimulating Factor (G-CSF), or an androgen (eg, danazol), within 2&#xD;
             weeks prior to dosing&#xD;
&#xD;
          -  HIV, hepatitis B or hepatitis C positive by serological testing at the screening visit&#xD;
             as defined in the protocol&#xD;
&#xD;
          -  Active tuberculosis, latent tuberculosis infection (LTBI) or history&#xD;
             incompletely-treated tuberculosis or LTBI&#xD;
&#xD;
          -  Active infection as defined in the protocol including COVID-19&#xD;
&#xD;
        Note: Other protocol-defined inclusion/ exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Capital Area</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Capital Area</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Capital Area</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Capital Area</state>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppressive therapy (IST)</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

